- Home
- RDZN vs TNXP Comparison
RDZN vs TNXP Comparison
Compare RDZN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- TNXP
- Stock Information
- Founded
- RDZN 2015
- TNXP 2007
- Country
- RDZN United States
- TNXP United States
- Employees
- RDZN N/A
- TNXP N/A
- Industry
- RDZN Blank Checks
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- RDZN Finance
- TNXP Health Care
- Exchange
- RDZN Nasdaq
- TNXP Nasdaq
- Market Cap
- RDZN 86.1M
- TNXP 71.6M
- IPO Year
- RDZN N/A
- TNXP N/A
- Fundamental
- Price
- RDZN $1.11
- TNXP $15.41
- Analyst Decision
- RDZN Strong Buy
- TNXP Strong Buy
- Analyst Count
- RDZN 2
- TNXP 2
- Target Price
- RDZN $5.00
- TNXP $585.00
- AVG Volume (30 Days)
- RDZN 178.0K
- TNXP 1.7M
- Earning Date
- RDZN 02-12-2025
- TNXP 05-12-2025
- Dividend Yield
- RDZN N/A
- TNXP N/A
- EPS Growth
- RDZN N/A
- TNXP N/A
- EPS
- RDZN N/A
- TNXP N/A
- Revenue
- RDZN $42,893,256.00
- TNXP $10,094,000.00
- Revenue This Year
- RDZN $4.52
- TNXP $74.31
- Revenue Next Year
- RDZN $53.72
- TNXP $82.61
- P/E Ratio
- RDZN N/A
- TNXP N/A
- Revenue Growth
- RDZN 2.79
- TNXP 29.94
- 52 Week Low
- RDZN $0.71
- TNXP $6.76
- 52 Week High
- RDZN $6.67
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- RDZN 48.30
- TNXP 45.80
- Support Level
- RDZN $0.96
- TNXP $16.36
- Resistance Level
- RDZN $1.38
- TNXP $31.87
- Average True Range (ATR)
- RDZN 0.13
- TNXP 4.33
- MACD
- RDZN 0.02
- TNXP -0.67
- Stochastic Oscillator
- RDZN 32.14
- TNXP 4.19
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.